Pediatric psychopharmacology for primary care

Introduction
	Target Audience
	Why Now?
	What Does This Book Contribute?
	References
Part 1: Before Prescribing
	Chapter 1: Getting Started
		Guiding Psychopharmacology Principles
		Additional Guiding Principles
		Organization and Overview
		Selected Changes and Updates in Third Edition
	Chapter 2: Conceptual Framework for Prescribing Psychotropic Medications
		Rationale for the Conceptual Framework
		Group 1 Medications for Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression
		Group 2 Medications
		Group 3 Medications
		References
	Chapter 3: Making a Diagnosis
		Overview
		Diagnosis of Common Disorders: ADHD, Anxiety Disorders, and Depression
		Diagnosis of Common Comorbidities of ADHD, Anxiety Disorders, and Depression
		Recognizing Other Psychiatric Disorders
		Determine if Medication Is Indicated
		Recognize Need for Referral
		References
	Chapter 4: Laying the Groundwork
		Formulation
		Feedback
		Nonmedication Interventions
		Informed Consent
		Specific Consent Issues
		Off-label Prescribing
		US Food and Drug Administration Boxed Warnings
		Triage for Psychiatric and Social Emergencies
		Important Considerations for Safe and Effective Prescribing
		References
Part 2: Group 1 Medications for Specific Diagnoses: Attention-Deficit/Hyperactivity Disorder, Anxiety, and Depression
	Chapter 5: Group 1 Medications for Attention-Deficit/Hyperactivity Disorder
		General Guidance
		Methylphenidate
		Amphetamine
		Guanfacine
		Clonidine
		Atomoxetine
		Viloxazine
		Summary
		References
	Chapter 6: Group 1 Medications for Anxiety and Depression
		General Guidance
		Group 1 Selective Serotonin Reuptake Inhibitors
		Group 1 Serotonin and Norepinephrine Reuptake Inhibitor: Duloxetine
		Summary
		References
Part 3: Group 2 and Group 3 Medications
	Chapter 7: Group 2 Medications: FDA-Approved Antipsychotics and Mood Stabilizers
		Rationale
		Antipsychotics
		The Mood Stabilizer Lithium
		Summary
		References
	Chapter 8: Group 3 Medications: Others Commonly Prescribed
		Other Antidepressants
		Other Antipsychotics
		Other Mood Stabilizers
		Anxiolytics
		Sleep Aids
		Future Considerations
		References
Part 4: After Prescribing: Midcourse Corrections
	Chapter 9: Fine Tuning Treatment
		Reevaluate Therapies
		Reevaluate Medication
		Discontinuing Group 1 Medications
		Switching Group 1 Medications
		When to Consider Group 2 Antipsychotics or Lithium
		When to Consider Group 3 Medications Without FDA Approval for Use in Youth
		When to Consider Drug Levels or Genetic Testing
		Can Genotyping Improve Medication Response?
		When to Consider Consultation or a Second Opinion
		References
	Chapter 10: Managing Treatment Impasses
		Reassess Diagnoses
		Complex Psychosocial Presentations
		Expert Consultation or Referral
		Reference
Appendixes
	A. Assessment and Symptom Monitoring Tools
	B. Resources for Clinicians
	C. Training Resources for Clinicians
	D. Quality Ratings for Psychotherapies and Efficacy Data for Medications
	E. Resources for Caregivers
	F. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Complete Criteria of Select Diagnoses
Index